CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients

被引：27

作者：

Mohammadzadeh, Adel ^{[1
]}

Rad, Isa Abdi ^{[2
]}

Ahmadi-Salmasi, Babak ^{[3
]}

机构：

[1] Urmia Univ Med Sci, Dept Immunol & Genet, Orumiyeh, Iran

[2] Urmia Univ Med Sci, Dept Genet, Orumiyeh, Iran

[3] Urmia Univ Med Sci, Dept Neurol, Imam Khomeini Hosp, Orumiyeh, Iran

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2018年 / 323卷

关键词：

CTLA-4; PD-1; TIM-3; Multiple sclerosis; T-CELL-ACTIVATION; MULTIPLE-SCLEROSIS; ASSOCIATION; MECHANISMS; GALECTIN-9; INFECTION; PROMOTES; DISEASE;

D O I：

10.1016/j.jneuroim.2018.08.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Multiple sclerosis (MS), is an autoimmune disorder of central nervous system (CNS) characterized by inflammation and demyelination. Self-tolerance impairment is considered to be induced by a combination of inherited susceptibility and environmental agents. In this work, we demonstrate that a reduction in the comparative expression of well-known inhibitory receptors (i.e., CTLA-4, PD-1, and TIM-3) is importantly linked with MS patients compared to healthy controls. The relative expression of interested genes was performed on peripheral blood mononuclear cells (PBMCs), by using quantitative real time-PCR (qRT-PCR). Our data high-lighted the role of inhibitory receptors in the maintenance of immune homeostasis in autoimmune disease.

引用

页码：105 / 108

页数：4

共 50 条

[21] Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
Jin, Shengming
Shang, Zhi
Wang, Wenwen
Gu, Chengyuan
Wei, Yu
Zhu, Yu
Yang, Chen
Zhang, Tiantian
Zhu, Yao
Zhu, Yiping
Wu, Junlong
Ye, Dingwei
JOURNAL OF IMMUNOTHERAPY, 2023, 46 (04) : 154 - 159
[22] Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
Sun, Michel M.
Levinson, Ralph D.
Filipowicz, Artur
Anesi, Stephen
Kaplan, Henry J.
Wang, Wei
Goldstein, Debra A.
Gangaputra, Sapna
Swan, Robert T.
Sen, H. Nida
Gordon, Lynn K.
OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 217 - 227
[23] PD-1 says goodbye, TIM-3 says hello
Diana Romero
Nature Reviews Clinical Oncology, 2016, 13 : 203 - 203
[24] Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1, and TIM-3 are markedly increased in basal cell carcinoma
Rapoport, Bernardo Leon
Malinga, Nonkululeko
Siwele, Shalete
Steel, Helen C.
Kwofie, Luyanda Li
Meyer, Pieter
Smit, Teresa
Anderson, Ronald
Kgokolo, Mahlatse
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
Varun Sasidharan Nair
Salman M. Toor
Rowaida Z. Taha
Hibah Shaath
Eyad Elkord
Clinical Epigenetics, 2018, 10
[26] DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
Nair, Varun Sasidharan
Toor, Salman M.
Taha, Rowaida Z.
Shaath, Hibah
Elkord, Eyad
CLINICAL EPIGENETICS, 2017, 10
[27] Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
Malinga, Nonkululeko Z.
Siwele, Shalete C.
Steel, Helen C.
Kwofie, Luyanda L., I
Meyer, Pieter W. A.
Smit, Teresa
Anderson, Ronald
Rapoport, Bernardo L.
Kgokolo, Mahlatse C. M.
TRANSLATIONAL ONCOLOGY, 2022, 19
[28] Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4
Guo, Jing
Xue, Zhonghui
Wang, Lie
CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (07) : 861 - 862
[29] Expression of the checkpoint receptors PD-1 and Tim-3 is increased in autoimmune blistering diseases
Ernst, N.
Schulz, A.
Friedrich, M.
Kasperkiewicz, M.
Gross, N.
Schmidt, E.
Sadik, C. D.
Zillikens, D.
Hartmann, K.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E78 - E79
[30] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, Anand
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)

← 1 2 3 4 5 →